TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Clinical trials for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOID CARDIOMYOPATHY trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial aims to tame deadly protein clogging chinese hearts
Disease control OngoingThis study is testing if a drug called eplontersen can help control a serious heart disease caused by abnormal protein buildup. It involves 64 Chinese adults with this condition. For the first 24 weeks, some will receive the drug and others a placebo, followed by a longer period …
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Major heart disease trial aims to slash deaths by clearing toxic protein
Disease control OngoingThis large, late-stage study is testing whether the drug ALXN2220 can help adults with a serious heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). The main goal is to see if the drug reduces the combined number of deaths from any cause and serious heart-relat…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
Landmark study sheds light on hidden heart disease in underserved communities
Knowledge-focused OngoingThis study created a database to better understand a rare and often missed heart disease called ATTR-CM. Researchers looked back at the medical records of 476 diverse patients from the Bronx who were tested for the condition between 2014 and 2023. The goal is to learn how the dis…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Sponsor: Montefiore Medical Center • Aim: Knowledge-focused
Last updated Mar 20, 2026 14:48 UTC